CurrentUnitedHealthcarePolicy N/A

Erythromycin 0.5% Ophthalmic Ointment — Neonatal GON Primary Prevention (Zero Dollar Cost-Share)

Defines coverage and zero dollar cost-share authorization for erythromycin 0.5% ophthalmic ointment when used for primary prevention of gonococcal ophthalmia neonatorum (GON) in newborns; affects members and providers submitting prior authorization for this medication.

Policy Summary

PayerUnitedHealthcare

PolicyErythromycin 0.5% Ophthalmic Ointment — Neonatal GON Primary Prevention (Zero Dollar Cost-Share)

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateSep 1, 2025

Next Review DateJun 1, 2025

Key ActionSubmit prior authorization with documentation that the medication will be administered to a newborn for primary prophylaxis to obtain zero dollar cost-share for up to 1 month.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

0.5%erythromycin concentration covered

zerocost share for covered use

1 moauthorization duration

USPSTFrecommendation source cited

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Erythromycin 0.5% Ophthalmic Ointment

Initial authorization criteria

Covered when ANY of the following are met

Primary prophylaxis intent: Member or health care provider intends to administer erythromycin 0.5% ophthalmic ointment to a newborn for the prophylaxis of gonococcal ophthalmia neonatorum

Approval grants zero dollar cost-share and deductible bypass for up to 1 month.

Coverage at zero dollar cost-share under this policy is limited specifically to the primary prevention use: administration of erythromycin 0.5% ophthalmic ointment to a newborn for the prophylaxis of gonococcal ophthalmia neonatorum. Other clinical uses or indications for erythromycin ophthalmic ointment are not described as eligible for zero dollar cost-share in this program.

Provider Actions, Authorization & Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required to approve zero copay with deductible bypass for erythromycin 0.5% ophthalmic ointment when intended for primary prophylaxis of gonococcal ophthalmia neonatorum (GON) in a newborn. Authorization is issued for zero copay with deductible bypass for up to 1 month from approval.

Medication: erythromycin 0.5% ophthalmic ointment
Approved duration: up to 1 month from approval

Step Therapy

No step therapy is specified. Erythromycin 0.5% ophthalmic ointment is the FDA‑approved standard for prophylaxis of gonococcal ophthalmia neonatorum and is the covered product for zero dollar cost‑share when criteria are met.

Documentation Required

Required Documentation

Documentation must confirm that the member (newborn) or the health care provider intends to administer the medication to the newborn for the primary prophylaxis of gonococcal ophthalmia neonatorum (GON).

Record or attestation that treatment is for primary prophylaxis of GON in a newborn
Provider statement or chart note indicating intent to administer erythromycin ophthalmic ointment at birth or shortly thereafter

Denial Risk

Denial Trigger: Not Primary Prophylaxis

Requests that are not for primary prophylaxis of gonococcal ophthalmia neonatorum in a newborn (for example, treatment of an established ocular infection or prophylaxis for non‑neonatal indications) may be denied for zero dollar cost‑share authorization.

Denial trigger: indication other than primary neonatal prophylaxis of GON
Examples: treatment of an active conjunctival infection, prophylaxis for older infants or adults

Clinical Background

Gonococcal ophthalmia neonatorum (GON) is a newborn ocular infection caused by Neisseria gonorrhoeae that can lead to rapid, severe eye injury. It can cause corneal scarring, ocular perforation, and blindness within a short time after birth. The U.S. Preventive Services Task Force recommends prophylactic ocular topical medication for all newborns to prevent GON, and erythromycin 0.5% ophthalmic ointment is the FDA-approved agent used for neonatal prophylaxis.

This policy supports that clinical risk context by authorizing zero copay with deductible bypass when the intent is to administer erythromycin 0.5% ophthalmic ointment to a newborn for primary prevention of GON; authorizations may be issued for up to 1 month from approval.

Definitions

Gonococcal ophthalmia neonatorum (GON) — definition and clinical significance

DefinitionA newborn ocular infection caused by Neisseria gonorrhoeae that can rapidly lead to corneal scarring, ocular perforation, and blindness (can occur as early as 24 hours after birth).

Clinical significanceCan cause corneal scarring, ocular perforation, and blindness within 24 hours of birth, making prompt prevention essential.

Prevention standardUSPSTF recommends prophylactic ocular topical medication for all newborns to prevent GON; ocular prophylaxis is mandated in most states and considered standard neonatal care.

Approved prophylactic agentErythromycin ophthalmic ointment 0.5% is the only FDA‑approved drug for prophylaxis of GON.

Policy relevanceCoverage programs provide zero dollar cost‑share for 0.5% erythromycin ophthalmic ointment when used for primary prevention of GON in newborns.

Initial Therapy Requirements

Initial therapy requirements

Initial coverage for primary prevention

Intent to treat newborn: Member or health care provider intends to administer erythromycin 0.5% ophthalmic ointment to a newborn for prophylaxis of gonococcal ophthalmia neonatorum

If met, authorization for zero copay with deductible bypass may be issued for up to 1 month.

Step Therapy

Step	Requirement / Note
1	No step therapy specified; erythromycin ophthalmic ointment is the FDA‑approved standard for prophylaxis of gonococcal ophthalmia neonatorum (GON).

Site of Care / Administration Setting

Note

Intended administration to newborn (hospital/clinic)

This program applies when the erythromycin ointment is intended to be administered to a newborn, typically at birth in a hospital or clinic outpatient setting, for prophylaxis of GON.